Drug development for Alzheimer’s disease has been a series of disappointments, with only faint glimmers of hope from pharmaceutical companies or academic labs. What causes the disease is still hotly debated, with the amyloid hypothesis losing believers after each new trial failure.
But before those drugs targeting amyloid plaques or tau tangles failed in human trials, they generally succeeded in preclinical studies — specifically, ones done with mice. Right now, about 160 mouse models for Alzheimer’s exist. But none is particularly good, experts say.